E.D.E.N

Endocrinologues Diabétologues de l'Ecole Niçoise
 
AccueilAccueil  PortailPortail  CalendrierCalendrier  FAQFAQ  RechercherRechercher  S'enregistrerS'enregistrer  MembresMembres  GroupesGroupes  Connexion  

Partagez | 
 

 Lipid and Glycemic Effects of Pioglitazone and rosiglytazone

Aller en bas 
AuteurMessage
albrengues
Bavard


Nombre de messages : 14
Localisation : Cagnes sur Mer
Date d'inscription : 24/05/2005

MessageSujet: Lipid and Glycemic Effects of Pioglitazone and rosiglytazone   Jeu 21 Juil - 10:27

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Diabetes Care. 2005;28(7):1547-1554.

Ronald B. Goldberg, MD; David M. Kendall, MD; Mark A. Deeg, MD, PHD; John B. Buse, MD, PHD; Anthony J. Zagar, MS; Jane A. Pinaire, PHD; Meng H. Tan, MD; Mehmood A. Khan, MD; Alfonso T. Perez, MD; Scott J. Jacober, DO


Abstract
Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either retrospective chart reviews or clinical trials not rigorously controlled for concomitant glucose- and lipid-lowering therapies. This study examines the lipid and glycemic effects of pioglitazone and rosiglitazone.
Research Design and Methods: We enrolled subjects with a diagnosis of type 2 diabetes (treated with diet alone or oral monotherapy) and dyslipidemia (not treated with any lipid-lowering agents). After a 4-week placebo washout period, subjects randomly assigned to the pioglitazone arm (n = 400) were treated with 30 mg once daily for 12 weeks followed by 45 mg once daily for an additional 12 weeks, whereas subjects randomly assigned to rosiglitazone (n = 402) were treated with 4 mg once daily followed by 4 mg twice daily for the same intervals.
Results: Triglyceride levels were reduced by 51.9 ± 7.8 mg/dl with pioglitazone, but were increased by 13.1 ± 7.8 mg/dl with rosiglitazone (P < 0.001 between treatments). Additionally, the increase in HDL cholesterol was greater (5.2 ± 0.5 vs. 2.4 ± 0.5 mg/dl; P < 0.001) and the increase in LDL cholesterol was less (12.3 ± 1.6 vs. 21.3 ± 1.6 mg/dl; P < 0.001) for pioglitazone compared with rosiglitazone, respectively. LDL particle concentration was reduced with pioglitazone and increased with rosiglitazone (P < 0.001). LDL particle size increased more with pioglitazone (P = 0.005).
Conclusions: Pioglitazone and rosiglitazone have significantly different effects on plasma lipids independent of glycemic control or concomitant lipid-lowering or other antihyperglycemic therapy. Pioglitazone compared with rosiglitazone is associated with significant improvements in triglycerides, HDL cholesterol, LDL particle concentration, and LDL particle size.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur http://www.albrengues.fr.st
 
Lipid and Glycemic Effects of Pioglitazone and rosiglytazone
Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» [Article] First Direct Observations of Quantum Effects in an Optomechanical System
» Nexavar
» decitabine + cellules T visant ny-eso-1
» L'isotope astatine-211
» Site "Laissez-les vivre" !

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
E.D.E.N :: ARCHIVES :: Corbeille-
Sauter vers: